Romedepsin (RM), A Hdaci, Significantly Increases The Expression Of NKG2D Ligands, MIC A/B, In Leukemia/Lymphoma Cells (LL), In Part Through The Glycogen Synthase Kinase-3 (GSK-3) Pathway, Resulting In Enhanced NK Cytotoxicity: Translational Approach For Adoptive NK Cell Immunotherapy  by Satwani, P. et al.
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p\0.05
1NK1 IL2(B) 16.3%68.6% 35.3%613%
1NK1 IRM(C) 62.6%614% 79.6%615%
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EFFECTIVE GRAFT-VERSUS-LEUKEMIA RESPONSES TO DONOR LYMPHO-
CYTE INFUSION ARE ASSOCIATED WITH PREEXISTING CD8 + T CELL
MARROW INFILTRATES
Hainz, U.1, Pozdnyakova, O.2, Aldridge, J.3, Kim, H.3, Canning, C.M.1,
Soiffer, R.J.4, Ritz, J.1,4, Alyea, E.P.4, Wu, C.J.1,4 1Dana-Farber Cancer
Institute, Boston, MA; 2Brigham and Women’s Hospital, Boston, MA;
3Dana-Farber Cancer Institute, Boston, MA; 4Dana-Farber Cancer
Institute, Boston, MA
Donor lymphocyte infusion is a highly effective treatment for
relapsed CML after allogeneic hematopoietic stem cell transplant
(HSCT), but predictors of response are unknown. In CML, mar-
row is the primary site of disease as well as a reservoir of high-
avidity antigen-specific memory B and T cells that can recognize
tumor antigens. We therefore examined serial bone marrow biop-
sies obtained before and after DLI for evidence of immune cell re-
sponse from 31 patients with relapsed CML following allogeneic
HSCT at our center between 1994-2001. All patients received
CD4 +DLI (3-10  107 CD4+ cells/kg) from the original stem
cell donor. Twenty-four patients achieved complete cytogenetic
remission following DLI, while 7 patients were non-responders.
Marrow biopsies, collected prior to DLI, within the first 2-3
months following DLI and approximately 1 year after DLI were
examined for cells expressing CD3, CD8, CD20 and CD138 by
immunohistochemistry, and were also scored for cellularity. DLI
responders demonstrated an increase in CD3 + T cells following
DLI compared to pre DLI (p5 0.07), while no increase was ob-
served among DLI non-responders. This infiltrate, appearing fol-
lowing DLI, consisted almost entirely of CD8 + T cells.
Significant changes in cells expressing CD20, CD138 were not ob-
served. Examination of the pre-treatment marrow revealed that in-
filtration by leukemia-reactive T cells was closely associated with
response to DLI. We detected a significantly increased percentage
of marrow-infiltrative CD3 + CD8 + T cells in pre-treatment mar-
row biopsies of responders (median 8%, range 2-20) compared to
non-responders (2.5%, range 1-2.5), p5 0.013. Degree of marrow
cellularity prior to DLI was also highly predictive of outcome.
While responders demonstrated a 50% median cellularity prior
to DLI, non-responders demonstrated more advanced relapse
with median cellularity at the time of DLI of 93% (p5 0.004).
Of the responders, we observed that 3 patients had 70% or greater
marrow cellularity, but also had 5% CD3 + CD8 + T cell infiltra-
tion, while all non-responders demonstrated \5% T cells, sug-
gesting that T cells can overcome advanced tumor cellularity in
some cases. These studies suggest that the presence of T cell infil-
trates in the marrow microenvironment is a significant predictor of
DLI response. This also implies that the effectiveness of DLI may
be mediated in part through the enhancement of pre-existing
GvL.Jurkat 1NK(A) 22.2%68% 63.7%622% 5:1-AvsC;
BvsD -
p\0.01
1NK1 IL2(B) 51%611% 102%621%
1NK1 IRM(C) 130%614% 174%639%
1NK_IL21 RM(D) 174%627% 208%634%415
ROMEDEPSIN (RM), A HDACI, SIGNIFICANTLY INCREASES THE EXPRES-
SION OF NKG2D LIGANDS, MIC A/B, IN LEUKEMIA/LYMPHOMA CELLS
(LL), IN PART THROUGH THE GLYCOGEN SYNTHASE KINASE-3 (GSK-
3) PATHWAY, RESULTING IN ENHANCED NK CYTOTOXICITY: TRANSLA-
TIONAL APPROACH FOR ADOPTIVE NK CELL IMMUNOTHERAPY
Satwani, P.1, Saha, A.1, Bavishi, S.1, Zhao, F.1, Ayello, J.1, van de
Ven, C.1, Cairo, M.S.1,2,3 1Columbia University, New York, NY; 2Co-
lumbia University, New York, NY; 3Columbia University, New York, NY
Introduction: Natural killer (NK) cells recognize malignant cells
through the tumor-associated expression of NKG2D-ligands, in-
cluding MIC A/B. However, tumor cells may shed MIC A/B and es-
cape immuno- surveillance. Glycogen synthase kinase-3 (GSK-3),
a constitutively active serine-threonine kinase with numerous func-
tions including regulation of cellular differentiation, stress and apo-
ptosis, also an important regulatory enzyme in the expression ofMIC
A/B in response to RM (Skov et al, Cancer Res, 2005).
Objective: To determine the expression of MIC A/B in response to
RM in various leukemia and lymphoma cells (LL), its influence on
NK cell mediated cytotoxicity and to investigate the role of the
GSK-3 pathway in the regulation of expression of MIC A/B in re-
sponse to RM.Methods: LL cells (106/ml, RS 4:11 [MLL-ALL], REH [pre-B cell
ALL], Jurkat [T-cell ALL], Toledo [DLBCL], Ramos [Burkitt’s
Lymphoma]) were exposed to RM (10 ng/mL) for 24 hours, followed
by FACS staining with PE-conjugated anti-MIC A/B. Peripheral
blood NK cells were isolated via magnetic separation followed by
IL-2 activation. Cytotoxicity assays (europium assay) were
performed at effector:target (E:T) ratio of 5-10:1. LL cells were
also pre-treated for 1 hour with 100 mM lithium chloride (LiCl),
a potent inhibitor of GSK-3 activity. Blocking studies were also per-
formed with anti-NKG2D antibodies.
Results: MIC A/B expression significantly increased in LL cells in
response to RM ([RS4:11 0.2% vs 82%, p\ 0.0001], [REH 0.2%
vs 46%, p5 0.0003], [Jurkat 1.12% vs 85%, p\ 0.0001], [Toledo
0.5% vs 15.8%, p5 0.0001], [Ramos 0.57% vs 67%, p5 0.0003]).
Enhanced expression of MIC A/B in response to RM was inhibited
when LL cells are pre-treated with LiCl (Jurkat [RM vs RM +LiCl]
85% vs 18%, p\0.0001; RS 4:11 [RM vs RM +LiCl] 82% vs 5%,
p\0.0001; Ramos [RM vs RM +LiCl] 67% vs 35%, p\0.0001).
Cytotoxicity assays revealed significant increases in-vitro cytotoxicty
in RS 4:11, Ramos and REH cells at E:T ratio of 5-10:1 (Table-1).
NKG2D receptor-blocking resulted in significant decrease in NK
cell mediated cytotoxicity in REH (p\0.03) and Ramos cells
(p\0.001). In-vivo experiments are underway.
Conclusion: Expression of MICA/B in LL cells is significantly in-
creased by RM leading to enhanced susceptibility for NKG2D-
MIC A/B mediated cytotoxicity by NK cells. Furthermore, up-reg-
ulation of MICA/B in LL cells secondary to RM exposure is in part
regulated by the GSK-3 signal transduction pathway.416
PRELIMINARY RESULTS OF A PHASE II TRIAL OFMONTELUKAST FOR THE
TREATMENT OF BRONCHIOLITIS OBLITERANS SYNDROME AFTER HSCT
Williams, K.M.1, Pavletic, S.Z.1, Hakim, F.T.1, Mitchell, S.A.2, Gea-
Banacloche, J.C.1, Comis, L.E.2, Cowen, E.W.3, Baird, K.4, Louie, A.5,
Shelhamer, J.H.6, Blacklock-Schuver, B.A.J.1, Avila, D.1,
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Bronchiolitis obliterans syndrome (BOS) after allogeneic HSCT
is a severe manifestation of cGVHD. Current treatments yield
poor and transient responses. Although the pathogenesis of BOS
after HSCT is unknown, a similar disease, BOS after lung trans-
plant is associated with elevated leukotriene levels. We present
